The FY2025 (Dec) proxy of Cytokinetics names 21 peer companies for pay. Among Cytokinetics and these peers, CEO pay was 6th highest of 9 and total shareholder return was 3rd highest of 9.
6th highest of 9in Cytokinetics and its pay peers, FY2025 (Dec) by CEO pay:
$4.8M$23.2M
3rd highest of 9in Cytokinetics and its pay peers, FY2025 (Dec) by total shareholder return:
$13$524
Pay peer group, FY2025 (Dec) proxy
| Halozyme Therapeutics | ||
| Madrigal Pharmaceuticals | ||
| BridgeBio Pharma | ||
| INSMED | ||
| Ionis Pharmaceuticals | ||
| Immunovant | ||
| Sarepta Therapeutics | ||
| Denali Therapeutics | ||
| Acadia Pharmaceuticals | Not disclosed | Not disclosed |
| Amicus Therapeutics, Inc. | Not disclosed | Not disclosed |
| Apellis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Ascendis Pharma A/S | Not disclosed | Not disclosed |
| Axsome Therapeutics | Not disclosed | Not disclosed |
| Blueprint Medicines Corporation | Not disclosed | Not disclosed |
| Crinetics Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| ImmunityBio, Inc. | Not disclosed | Not disclosed |
| Intra-Cellular Therapies, Inc. | Not disclosed | Not disclosed |
| Legend Biotech Corp | Not disclosed | Not disclosed |
| Ultragenyx Pharmaceuticals Inc. | Not disclosed | Not disclosed |
| Vaxcyte | Not disclosed | Not disclosed |
21 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.